DB17616ExperimentalProtein Based Therapies
Mubodina is an investigational drug developed by Adienne Pharma & Biotech. It is a recombinant human minibody directed against complement component C5. It was investigated in various conditions including primary... It was investigated in various conditions including primary membranoproliferative glomerulonephritis and typical hemolytic uremic syndrome.
- Also known as
- Neutralizing scFv dimer to C5 fused at the C terminal end to the Fc domains of human IgG1
Resolves to
Compound
Which companies are running trials of Mubodina, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account